13 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 Ardena appoints Paul Edwards as Chief People Officer Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO advancing precision medicines, today announces the appointment of Paul Edwards as Chief People Officer. He will lead Ardena’s global people strategy, strengthening organizational capability and supporting the company’s continued international growth. Paul brings over 30 years of Human Resources leadership experience in complex, science-driven organizations. He joins Ardena after 16 years at Catalent Pharma Solutions, where he most recently served as Vice President, Human Resources. In that role, he led international HR teams across multiple business units and geographies, shaping people strategies aligned with operational expansion, organizational design and leadership development. At Ardena, Paul will focus on strengthening leadership capability, building a high-performance culture and ensuring the organization is structured to support productivity, speed and scalability. His mandate includes simplifying structures, clarifying accountability and developing the talent and engagement frameworks required to enable efficient execution across the business. Jeremie Trochu, Chief Executive Officer of Ardena, commented: “I’m delighted to welcome Paul onto our team. His track record in leading global HR organizations within the biopharma services sector makes him a very strong addition to our executive team. As Ardena continues to expand its capabilities and footprint internationally, investing in our people, leadership and culture is essential to delivering for our customers. Paul will play a key role in ensuring our organization evolves in line with our strategic ambitions.” Paul Edwards added: “Ardena has a clear strategy and very strong scientific and technical foundations. I look forward to working with my new colleagues across the organization to further develop our leadership capability, support talent development and foster a high-performance culture that enables sustainable growth.” Paul holds a joint honours degree in Law and Politics from Durham University in the United Kingdom and is based in New Jersey, USA. NEWS Linerixibat has been granted Orphan Drug Designation in the US, EU and Japan, and priority review in China, for the treatment of cholestatic pruritus in patients with PBC. Marketing applications for linerixibat are currently under regulatory review in the US, EU, UK, China and Canada, based on positive data from the GLISTEN phase III trial. GLISTEN met primary and key secondary endpoints, demonstrating a rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo. The safety profile of linerixibat was consistent with previous studies and the mechanism of IBAT inhibition. Linerixibat is not currently approved anywhere in the world. Francesco Balestrieri, Chief Executive Officer, Alfasigma, said: “Alfasigma is committed to advancing rare and specialty care by developing and delivering innovative solutions that address some of the most complex healthcare challenges. With our deep hepatology expertise and strong global footprint, we are uniquely positioned to lead the worldwide commercialization of linerixibat. This agreement underscores our strategic focus on bringing meaningful new treatments to patients and improving outcomes for communities around the world.” Financial considerations Under the terms of the agreement, GSK will receive an upfront payment of $300 million, plus $100 million upon US FDA approval (expected prior to transaction closing, based on current PDUFA target approval date of 24 March 2026). Additionally, GSK is eligible to receive $20 million upon EU and UK approval, and up to $270 million in sales-based milestone payments. GSK will also earn tiered double-digit royalties on net sales worldwide. This transaction is subject to customary conditions, including applicable regulatory agency clearances such as under the HartScott-Rodino Act in the US.
RkJQdWJsaXNoZXIy MjY2OTA4MA==